• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Vance Terry

    3/14/25 5:44:01 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ENTA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Vance Terry

    (Last) (First) (Middle)
    C/O ENANTA PHARMACEUTICALS, INC.
    4 KINGSBURY AVENUE

    (Street)
    WATERTOWN MA 02472

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ENANTA PHARMACEUTICALS INC [ ENTA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/13/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $6.83 03/13/2025 A 15,700 (1) 03/13/2035 Common Stock 15,700 $0 15,700 D
    Explanation of Responses:
    1. Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 13, 2025), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2026 annual meeting of stockholders.
    Remarks:
    Exhibit 24 Power of Attorney filed herewith.
    /s/ Matthew Kowalsky as attorney-in-fact 03/14/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ENTA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENTA

    DatePrice TargetRatingAnalyst
    7/28/2025$20.00Buy
    H.C. Wainwright
    8/9/2023$14.00Neutral → Underweight
    JP Morgan
    8/8/2023$49.00 → $18.00Buy → Hold
    Jefferies
    12/9/2022$56.00Buy
    H.C. Wainwright
    7/6/2022$62.00In-line → Outperform
    Evercore ISI
    6/1/2022$39.00Underperform → In-line
    Evercore ISI
    2/9/2022$80.00 → $68.00Market Perform
    SVB Leerink
    1/13/2022$85.00 → $80.00Market Perform
    SVB Leerink
    More analyst ratings

    $ENTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the pricing of an upsized underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares are being offered by Enanta. The offering is expected to close on October 2, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds to Enanta from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $65.0 million. In addition, Enanta has granted the underwri

    9/30/25 9:00:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced it has commenced an underwritten public offering for $50.0 million of shares of its common stock. All of the shares are being offered by Enanta. In addition, Enanta intends to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be compl

    9/30/25 4:11:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

    6.7-Day Improvement in Time to Complete Resolution of All RSV Symptoms for Patients with Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), or Age ≥75 Statistically Significant Improvement in Patient Global Impression of Severity Score Lower Hospitalization Rate for Patients Treated with Zelicapavir (1.7%) vs. Placebo (5%) 4- to 5-Day Faster Median Time to Undetectable Viral Load with Zelicapavir vs. Placebo Management to Host Conference Call and Webcast Today at 8:30 a.m. ET Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases,

    9/29/25 6:30:00 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Enanta Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of Enanta Pharmaceuticals with a rating of Buy and set a new price target of $20.00

    7/28/25 8:57:53 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals downgraded by JP Morgan with a new price target

    JP Morgan downgraded Enanta Pharmaceuticals from Neutral to Underweight and set a new price target of $14.00

    8/9/23 7:32:28 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals downgraded by Jefferies with a new price target

    Jefferies downgraded Enanta Pharmaceuticals from Buy to Hold and set a new price target of $18.00 from $49.00 previously

    8/8/23 6:35:35 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Capps Kathleen S. claimed ownership of 5,829 shares (SEC Form 3)

    3 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

    9/8/25 6:01:31 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Trout Harry R. Iii claimed ownership of 10,912 shares (SEC Form 3)

    3 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

    9/8/25 6:00:59 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rottinghaus Scott T. covered exercise/tax liability with 2,217 shares, decreasing direct ownership by 9% to 22,590 units (SEC Form 4)

    4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

    8/8/25 4:35:45 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Luly Jay R. bought $256,050 worth of shares (45,000 units at $5.69), increasing direct ownership by 6% to 846,638 units (SEC Form 4)

    4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

    2/12/25 8:09:35 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    Leadership Updates

    Live Leadership Updates

    View All

    Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer. In this role, he will lead all legal and compliance activities for Enanta, as well as provide strategic guidance and corporate governance oversight. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430622885/en/Matthew P. Kowalsky, Chief Legal Officer, Enanta Pharmaceuticals, Inc. (Photo: Business Wire) "I'm pleased to welcome Matt to Enanta. The breadth of his legal expertise ac

    4/30/24 7:00:00 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced the appointment of Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer, effective today, August 8, 2022. With over 20 years of experience in drug development across a broad range of therapeutic areas, Dr. Rottinghaus will lead the development, regulatory, clinical and medical functions in support of Enanta's pipeline. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220808005491/en/Scott T. Rottinghaus, M.D., Senior Vi

    8/8/22 4:00:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals Announces the Appointment of Brendan Luu as Senior Vice President, Business Development

    WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of Brendan Luu as Senior Vice President, Business Development and member of the company’s senior management team. Mr. Luu brings more than 20 years of diversified business development and sales and marketing experience in the pharmaceutical and technology fields to Enanta, spanning a broad range of therapeutic areas, asset stages and deal structures. “It is an ideal time to welcome Brendan to the Enanta team, particularly as we prepare for a catalys

    1/26/21 7:00:00 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Enanta Pharmaceuticals Inc.

    SC 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)

    11/14/24 4:03:02 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Enanta Pharmaceuticals Inc.

    SC 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)

    10/17/24 4:31:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Enanta Pharmaceuticals Inc. (Amendment)

    SC 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)

    2/14/24 2:26:49 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    Financials

    Live finance-specific insights

    View All

    Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

    6.7-Day Improvement in Time to Complete Resolution of All RSV Symptoms for Patients with Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), or Age ≥75 Statistically Significant Improvement in Patient Global Impression of Severity Score Lower Hospitalization Rate for Patients Treated with Zelicapavir (1.7%) vs. Placebo (5%) 4- to 5-Day Faster Median Time to Undetectable Viral Load with Zelicapavir vs. Placebo Management to Host Conference Call and Webcast Today at 8:30 a.m. ET Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases,

    9/29/25 6:30:00 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

    Conference Call and Webcast to Discuss Data on Monday, September 29 at 8:30 a.m. ET Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced the company will hold a conference call and webcast on Monday, September 29 at 8:30 a.m. ET to share topline results from RSVHR, a Phase 2b study evaluating zelicapavir for the treatment of respiratory syncytial virus (RSV) in high-risk adults. Conference Call and Webcast Information The live webcast can be accessed at "Events & Presentations" in the investors section of Enanta's website. To participate by phone

    9/26/25 4:01:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025

    On Track to Report Topline Data for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in September On Track to Select a STAT6 Development Candidate in 2H 2025 Conducting IND Enabling Studies of EPS-1421, an Oral KIT Inhibitor Candidate, in Development for the Treatment of Chronic Spontaneous Urticaria and Other Mast Cell Driven Diseases Operations Supported by Cash and Marketable Securities Totaling $204.1 Million at June 30, 2025, as well as Continuing Retained Royalties Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and i

    8/11/25 4:02:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    SEC Filings

    View All

    SEC Form 424B5 filed by Enanta Pharmaceuticals Inc.

    424B5 - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

    9/30/25 4:43:53 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

    9/29/25 8:20:18 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

    9/29/25 6:51:36 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care